Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 9/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21546423 | 0.85 | OPRK1 (0.38) | OPRK1GRM4ACACBCHRM3PDE4A | |
| SCHEMBL18487129 | 0.80 | ACACB (0.46) | OPRK1JAK2JAK1TYK2ACACB | |
| SCHEMBL29414900 | 0.80 | ACACB (0.46) | OPRK1JAK2JAK1TYK2ACACB | |
| SCHEMBL17512512 | 0.80 | JAK2 (0.36) | OPRK1JAK2JAK1TYK2GRM4 | |
| SCHEMBL20244771 | 0.78 | CHRM3 (0.41) | OPRK1CHRM3PDE4APDE4BPDE4C | |
| SCHEMBL4137416 | 0.77 | OPRK1 (0.42) | OPRK1 | |
| SCHEMBL24240547 | 0.77 | ACACB (0.37) | OPRK1GRM4ACACB | |
| SCHEMBL15294737 | 0.76 | OPRK1 (0.61) | OPRK1 | |
| SCHEMBL21546394 | 0.75 | OPRK1 (0.40) | OPRK1ACACB | |
| SCHEMBL19689526 | 0.75 | OPRK1 (0.44) | OPRK1JAK2JAK1TYK2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355693-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | OPRK1 662/4885JAK2 2314/4885JAK1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.